Proactive Investors - Run By Investors For Investors

Mediclinic won’t make a fresh swoop for Spire as takeover talks break down

Mediclinic hinted last week that it was considering reviving its interest in Spire after having a £1.2bn offer rejected last month
Murrayfield hospital sign
Mediclinic snapped up a stake in Spire back in 2015 as part of its plan to expand outside of its home South African market

Shares in Mediclinic International Plc (LON:MDC) headed lower on Monday after the company said it will not make a further offer for fellow private hospital group Spire Healthcare Group PLC (LON:SPI).

After having an offer turned down in October, South Africa-based group Mediclinic said last week it was mulling the possibility of a fresh swoop although it has now canned that idea following a breakdown in talks.

READ: Mediclinic downgraded to 'neutral' by JP Morgan Cazenove

South Africa-based Mediclinic saw its share price fall 35% to 539p in early deals, while Spire shares dived by 5% to 256.3p.

At the end of last month, Spire – in which Mediclinic holds a stake of almost 30% – rejected an offer which valued it at £1.2bn.

As a result, Mediclinic had until 5pm today (UK time) to either make a new offer or walk away. By choosing the latter, under City takeover rules it now has to wait another six months before it can make another bid unless there is a change in circumstances.

READ: Mediclinic gets a shot in the arm from reported Adu Dhabi regulatory change

“Mediclinic is disappointed that it could not reach an agreement with the independent directors of Spire,” the company said after talks between the two collapsed over the weekend.

Mediclinic added that it will remain a “supportive shareholder”.

View full MDC profile View Profile

Mediclinic International Plc Timeline

Related Articles

An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use